The pace of change to value-based payments has been happening quickly, but the real test is whether or not these payments produce higher quality and more affordable care, said Suzanne Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform.
The pace of change to value-based payments has been happening quickly, but the real test is whether or not these payments produce higher quality and more affordable care, said Suzanne Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform.
Transcript
Has the move to value-based payments been happening as quickly as you expected?
When we got started in 2010, there was so little value-based payment; It was maybe between 1% and 3% of payments, and in the last 7-and-a-half, 8 years, we’re at 50% now. So, I think that’s a pretty remarkable and fast change to how were paying healthcare providers. The big question is, how well are these payments working to produce the higher quality and more affordable care that we hoped they would?
What have been the outcomes seen so far in the move to value-based payments?
As a whole, I would say the outcomes of these value-based payment movement and the growth of payment reform are mixed. So far, we’ve seen some really great examples of improvements in certain quality measures and even more efficient use of resources. But, we’ve also seen examples of where there were really disappointing results, and we can’t even specify the positive or negative results by payment method. Even within a program and bundled payment, you might see some quality measures getting better, and some not. In an ACO environment supported by shared savings, you might see that length of stay in the hospital was reduced, but there was no impact on adherence to guideline for diabetes care. So far, were seeing real mixed results, even by payment methods.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen